Clinical trials: sponsored by Tongji Hospital
HCC - Hepatocellular Carcinoma
A Prospective Observational Cohort Study on Dynamic CD8+ T-cell Profiling and Multi-omics Biomarkers for Predicting Conversion Therapy Response in Unresectable Hepatocellular Carcinoma
This study aims to identify early predictors for successful liver cancer treatment conversion. We will track changes in immune cells (CD8+ T-cells) in the blood during chemotherapy infusion (HAIC/TACE) combined with…
- Trial name
- NCT07117279
- Volunteers
- 120 people
- Sponsor
- Tongji Hospital
Airway Management
A Clinical Study on Predicting the Depth of Double-Lumen Tube Insertion Based on Height and Sitting Height
This study employed a combined observational derivation and randomized validation approach to establish and evaluate predictive models for the depth of DLT insertion (Figure 1).
- Trial name
- NCT06709053
- Testing
- standing hight-based, sitting height-based, CT-based
- Where
- China
- Volunteers
- 418 people
- Sponsor
- Tongji Hospital
Gynecological Day Surgery
The Effect of Remimazolam on Postoperative Sleep Quality
A large amount of clinical evidence shows that after surgery, especially major surgery, the sleep quality of patients often drops significantly immediately, with the most obvious decline on the first night after surgery, which…
- Trial name
- NCT07094945
- Testing
- Remimazolam, Propofol
- Volunteers
- 260 people
- Sponsor
- Tongji Hospital
Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
This study aims to develop and validate a deep learning model to predict pathological complete response (pCR) in patients with esophageal squamous cell carcinoma who have undergone neoadjuvant immunochemotherapy.
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy, Pathological Complete Response, Deep Learning
- Trial name
- DL-ESCC (NCT07088354)
- Testing
- The high-throughput extraction of large amounts of quantitative image features from medical images
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
This is a clinical trial that aims to evaluate whether adding a bile acid called tauroursodeoxycholic acid (TUDCA) can improve the effects of immunotherapy in patients with advanced liver cancer (hepatocellular carcinoma).
- Trial name
- NCT07064668
- Testing
- TUDCA (Tauroursodeoxycholic Acid) Supplementation, Immune checkpoint inhibitor (ICI)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Liver Cirrhosis, Liver Cancer
Development of a Set of Auxiliary Decision-making System for the Perioperative Period of Hepatectomy Based on Static CT and Artificial Intelligence.
The study will prospectively recruit patients with chronic liver disease and liver cancer for static CT scans to establish a high-definition CT database.
- Trial name
- NCT07056270
- Testing
- static CT scans
- Volunteers
- 500 people
- Sponsor
- Tongji Hospital
B-ALL, B-NHL
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma / leukemia.
- Trial name
- NCT06689917
- Testing
- JY231 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tongji Hospital
Advanced Digestive System Tumor
A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors
This is a prospective, open-label, exploratory, phase II basket clinical trial designed to evaluate the efficacy and safety of sintilimab in combination with pyrotinib with or without chemotherapy in patients with advanced…
- Trial name
- CCGLC-018 (NCT07053150)
- Testing
- Sintilimab, Pyrotinib, Optional Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tongji Hospital
Glioblastoma
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma
A Phase II clinical study is planned to evaluate the efficacy and safety of fluzoparib combined with temozolomide in newly diagnosed glioblastoma patients after completing standard concurrent chemoradiotherapy (CCRT), explore the…
- Trial name
- NCT07047066
- Testing
- Fluzoparib with Temozolomide
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
B-cell Acute Lymphoblastic Leukemia
A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT119X(including CT1190-P and CT1192) CAR-T Cell therapy, in Patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia.
- Trial name
- NCT07043218
- Testing
- Chimeric Antigen Receptor T Cells (CAR-T)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Tongji Hospital, Tongji University School of Medicine
Hypotension During Surgery
Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in Adults
Research objective: To explore the safety and dose exploration of Remimazolam Tosilate for Injection for induction and maintenance of general anesthesia in elective short-term surgery in adults.
- Trial name
- NCT04908553
- Testing
- Remimazolam Tosilate for Injection 0.1mg/kg, Remimazolam Tosilate for Injection 0.15mg/kg, Remimazolam Tosilate for Injection 0.2mg/kg
- Where
- China
- Volunteers
- 650 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma (HCC)
Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma
This retrospective observational study aims to evaluate whether artificial intelligence (AI) models can predict aggressive recurrence in patients who underwent liver resection for early-stage hepatocellular carcinoma (HCC).
- Trial name
- NCT07030842
- Testing
- liver resection
- Where
- China
- Volunteers
- 579 people
- Sponsor
- Tongji Hospital
Postherpetic Neuralgia ( PHN ), Lymphatic System Disorder
Early Screening Markers of Herpes Zoster Neuralgia
Herpes zoster (HZ), especially postherpetic neuralgia, is one of the most typical types of clinical neuralgia. The incidence rate of HZ in China is approximately 7.7%. Among them, 29.8% of HZ patients eventually develop PHN.
- Trial name
- NCT07038707
- Testing
- Extract the serum and feces of the patients for standard screening of early biomarkers, Meningeal lymphatic vessel imaging
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Ovarian Cancer
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Fluzoparib has been approved for the first-line maintenance treatment of advanced ovarian cancer in the full population . Previous studies have demonstrated that anti-angiogenic agents enhance tumor cell sensitivity to PARP…
- Trial name
- NCT06954584
- Testing
- Bevacizumab, Fluzoparib Monotherapy, Dietary Intervention
- Where
- 2 sites in China
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Etomidate Combined With Propofol, Hypertension
Safety of Etomidate-propofol Mixture vs. Propofol for Total Intravenous Anesthesia in Elderly Patients Undergoing Abdominal Surgery
The purpose of this study is to access the safety of etomidate - propofol mixture vs propofol for total intravenous anesthesia in elderly patients undergoing abdominal surgery.
- Trial name
- NCT07019246
- Testing
- EP mixture, Propofol
- Where
- China
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Genital Neoplasms, Female, Uterine Cervical Neoplasms
Patient Journey in Advanced Gynecologic Cancers
This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including…
- Conditions
- Genital Neoplasms, Female, Uterine Cervical Neoplasms, Endometrial Carcinoma
- Trial name
- NCT07015593
- Testing
- interview
- Where
- 4 sites in China
- Volunteers
- 780 people
- Sponsor
- Tongji Hospital
Ovarian Cancer
Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer
This study is an open-label, multicenter, umbrella study aimed to evaluate the combined, biomarker-driven, targeted treatment efficiency of Pamiparib, Bevacizumab, Tislelizumab, and Nab-paclitaxel in patients with…
- Trial name
- BRIGHT (NCT05044871)
- Testing
- Pamiparib, Bevacizumab, Tislelizumab
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Tongji Hospital
HCC
A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence
For patients with early- to mid-stage hepatocellular carcinoma (HCC), the five-year postoperative recurrence and metastasis rate remains as high as 70%, significantly impacting patient prognosis.Therefore, perioperative therapy…
- Trial name
- NCT07009470
- Testing
- Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar), TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Tongji Hospital
B Cell Lymphoma
Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
This is an open-label phase1 study to assess the safety and efficacy of U01(ssCART-19) cell therapy in the treatment of patients with refractory or recurrent B-cell lymphoma .
- Trial name
- NCT06987916
- Testing
- ssCART-19
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Tongji Hospital, Tongji University School of Medicine
Biliary Tract Cancer, Advanced Cancer
Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Brief Summary The goal of this clinical trial is to test whether the combination of Envafolimab (an immunotherapy drug), chemotherapy (gemcitabine + cisplatin), and simvastatin can help treat advanced biliary tract cancer (BTC)…
- Trial name
- NCT07003815
- Testing
- Envafolimab + Gemcitabine + Cisplatin + Simvastatin
- Volunteers
- 62 people
- Sponsor
- Tongji Hospital